FAAS yields 2469.14% · ABBV yields 3.06%● Live data
📍 FAAS pulled ahead of the other in Year 1
Combined, FAAS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FAAS + ABBV for your $10,000?
DigiAsia Corp. develops an AI embedded finance platform in Southeast Asia. It offers B2B fintech platform for bill payments, supply chain payments, and branchless banking solutions for merchants, partners, and customers; digital wallets; QRIS Payment as a Service; Cash Management system for ERP system that allows users to create a closed-loop cash management system; Digital Product & Billers, which allows users to purchase digital products or pay bills to multiple issuers or billers; and Remittance Product that enables users to transfer funds from their application cash-to-cash, cash-to-account, account-to-cash, and account-to-account. The company also provides B2B Loan product for micro, small, and medium enterprises; Gold saving products; Virtual Card Number to generate a digital invoice for customers to accept payment over internet transactions; Buy Now Pay Later; e-KYC module to Onboard new customers securely in compliance with regulation; Cash in & Cash Out points; KasPro Bank for Banks and FSI to utilize their networks of retail outlets onboarded as licensed digital banking agents to offer cash-in & cash-out points to serve micro small, and medium enterprises. DigiAsia Corp. is headquartered in Jakarta, Indonesia.
Full FAAS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.